Representation in Clinical Trials

Research institutions have long struggled with accurate population representation in clinical trials. The growing proliferation of digital in healthcare ecosystems makes this more likely, but it is not perfect. UCLA Health’s Dr. Arash Naeim and Dr. Medell Briggs-Malonson share their efforts to progress the intersectionality of health technology and health audience in clinical trials and beyond. Verizon’s Robin Goldsmith and Ned Chini round out this conversation with the role devices and connectivity play in achieving representation.

Recent Episodes

Denials are no longer a slow leak in the revenue cycle—they’re a fast-moving, rule-shifting game controlled by payers, and hospitals that don’t model denial patterns in real time end up budgeting around losses they could have prevented. PayerWatch’s four-digit, client-verified ROI in 2024 shows what happens when a hospital stops reacting claim by…

Health insurers love to advertise themselves as guardians of care, but the real story often begins when a patient’s life no longer fits neatly into a spreadsheet. In oncology especially, “coverage” isn’t a bureaucratic checkbox—it’s the fragile bridge between a treatment that finally works and a relapse that can undo years of grit…

In “Fighting for Coverage,” a patient describes a double war: the physical fight to stay alive and the bureaucratic fight to prove to an insurer that her life is worth the cost. Her account spotlights a core tension in the U.S. system—coverage decisions are increasingly shaped by prior authorizations and desk-based reviewers who…